Bristol-Myers Squibb Company Share Price

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse 21:00:02 14/06/2024 BST 5-day change 1st Jan Change
41.2 USD -0.68% Intraday chart for Bristol-Myers Squibb Company -0.68% -19.70%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2024 * 46.09B 3,633B Sales 2025 * 46.06B 3,631B Capitalization 83.52B 6,584B
Net income 2024 * -5.41B -427B Net income 2025 * 10.22B 806B EV / Sales 2024 * 2.66 x
Net Debt 2024 * 39.03B 3,077B Net Debt 2025 * 31.68B 2,497B EV / Sales 2025 * 2.5 x
P/E ratio 2024 *
-15.7 x
P/E ratio 2025 *
7.79 x
Employees 34,100
Yield 2024 *
5.84%
Yield 2025 *
6.13%
Free-Float 69.27%
More Fundamentals * Assessed data
Dynamic Chart
Bristol Myers: FDA approval for treatment CF
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors MT
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval DJ
Evotec to Receive $20 Million Under Neuroscience Partnership with Bristol Myers Squibb MT
Evotec Gets $20 Million Milestone Payment in Neurodegenerative Disease Collaboration With Bristol Myers Squibb MT
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb CI
Transcript : Bristol-Myers Squibb Company Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 11:20 AM
ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial MT
Geron shares surge after U.S. FDA approves blood disorder drug RE
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers MT
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers CI
Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients MT
Bristol Myers: positive results in liver cancer CF
Bristol Myers Squibb Announces Opdivo Plus Yervoy Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial CI
Envisagenics, Inc. announced that it has received $25 million in funding from New York City Economic Development Corporation, Third Kind Venture Capital, Red Cell Management, LLC, Bristol-Myers Squibb Company CI
More news
1 day-0.68%
1 week-0.68%
Current month+0.27%
1 month-7.52%
3 months-21.28%
6 months-19.04%
Current year-19.70%
More quotes
1 week
40.75
Extreme 40.75
43.19
1 month
39.91
Extreme 39.91
44.30
Current year
39.91
Extreme 39.91
55.04
1 year
39.91
Extreme 39.91
66.38
3 years
39.91
Extreme 39.91
81.44
5 years
39.91
Extreme 39.91
81.44
10 years
39.91
Extreme 39.91
81.44
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 31/01/15
Director of Finance/CFO 55 19/11/19
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 66 19/11/19
Director/Board Member 59 31/03/16
Director/Board Member 59 31/08/20
More insiders
Date Price Change Volume
14/06/24 41.2 -0.68% 14,271,103
13/06/24 41.48 -2.19% 17,023,712
12/06/24 42.41 -1.42% 9,433,173
11/06/24 43.02 +1.06% 12,637,053
10/06/24 42.57 +2.63% 13,461,843

Delayed Quote Nyse, June 14, 2024 at 09:00 pm

More quotes
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.2 USD
Average target price
53.19 USD
Spread / Average Target
+29.11%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW